This article is more than 5 years old. Information may no longer be current.
Ocular Therapeutix to evaluate Dextenza in treatment of allergic conjunctivitis
Click Here to Manage Email Alerts
Ocular Therapeutix has begun enrollment in a phase 3 safety and efficacy trial of Dextenza, an allergic conjunctivitis treatment candidate, the company announced in a press release.
Dextenza (sustained-release dexamethasone 0.4 mg) is delivered to the ocular surface for up to 30 days via a bioresorbable intracanalicular depot.
Drug vs. placebo will be assessed in the 30-day trial, with primary endpoints of ocular itching and conjunctival redness at day 7 after insertion in subjects who exhibit chronic signs and symptoms of allergic conjunctivitis and are exposed to allergen. Secondary measurements will be made at day 14 and days 27 to 30.
“Severe allergy patients are often prescribed topical steroids for their condition, and we believe Dextenza may serve as an attractive alternative in treating allergic conjunctivitis due to its constant yet low-dose elution of therapy over an extended period,” Amar Sawhney, PhD, president and CEO of Ocular Therapeutix, said in the release.
Collapse
Click Here to Manage Email Alerts